

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

This guidance document by the British Menopause Society provides an overview of the management of women experiencing estrogen deficiency symptoms and arthralgia following a breast cancer diagnosis. It is now recommended breast cancer patients are referred to health care professionals with an expertise in menopause for management of such symptoms, which in turn often involves liaison with patients' breast cancer teams.<sup>1</sup> However, as many women initially present to primary health care professionals for advice, this statement is aimed to support the latter in such consultations by providing information about symptom aetiology, current management strategies and controversies and identifying useful practice points.

## Key points

1. An early menopause, estrogen deficiency symptoms and arthralgia are common side effects of systemic breast cancer therapies.
2. Symptoms may persist for the duration of treatment and in some cases continue after treatment completion.
3. The NICE Menopause Guidance [NG23] recommends referral of women to a healthcare professional with expertise in gynaecological endocrinology for counselling about the risk of developing an early menopause and the management of symptoms associated with breast cancer treatment.
4. Lifestyle measures and non-hormonal interventions should be first-line management for estrogen deficiency symptoms but if these are ineffective systemic hormone replacement therapy or low-dose topical estrogen may be considered but only after taking specialist advice.
5. Lifestyle measures such as weight loss and increased exercise may also improve arthralgias associated with aromatase inhibitors and tamoxifen
6. Switches to endocrine breast cancer treatment may alleviate symptoms of estrogen deficiency and arthralgia but these should only be instigated in secondary care by the breast specialist team.

## Introduction

Breast cancer is the most commonly diagnosed female malignancy in the UK. Despite the risk of diagnosis increasing rapidly in the third and fourth decades, it is predominantly a condition of the post-menopause as approximately 80% of cases occur in women over the age of 50.<sup>2</sup> The development, introduction and now widespread use of breast cancer systemic therapies in the management of early stage disease, the aim of which is to eradicate dormant occult micro-metastases, is the most significant contributor to the improvements in breast cancer survival.<sup>3,4</sup> Unfortunately, estrogen deficiency symptoms and arthralgia may be induced, or pre-existing symptoms exacerbated by these therapies and result in their discontinuation.<sup>5</sup> Treatment of vasomotor symptoms and vulvo-vaginal atrophy may be problematic as hormone replacement therapy (HRT) is contra-indicated in women with estrogen responsive breast cancer, the efficacy of some HRT alternatives to treat vasomotor symptoms is not widely appreciated, and there is lack of consensus about the optimal management of arthralgia.<sup>6,7</sup> Effective patient care, however, requires more than simply advising about potential interventions. For many women, opportunity to have informed discussion with a health care professional about the reasons for symptom development and their duration can be of therapeutic benefit in itself. However, these discussions may be difficult if the clinician has little knowledge concerning the management of breast cancer.<sup>8</sup>

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

## Principles of early breast cancer management

The majority of women presenting with breast cancer in the UK have early stage disease, that is they do not have detectable systemic metastases. Management, therefore, consists of (1) local control for the prevention of local complications and recurrence in the breast and ipsilateral axilla using surgery and radiotherapy and (2) adjuvant systemic therapy to prevent the development of distant metastases by eradicating occult, micro-metastases.<sup>3</sup> It is systemic and not local control therapy, which confers survival benefit. The range of treatments that can be prescribed for the latter include chemotherapy, anti-estrogenic endocrine therapy, gonadotrophin-releasing hormone agonists [GnRH<sub>a</sub>] and targeted therapy such as Herceptin (trastuzumab).<sup>3</sup>

## Selection of adjuvant therapy

This is individualised for every patient, based on their breast cancer receptor status and prognostic factors. Most women are recommended to have a combination of therapies.<sup>3,9</sup>

## Breast cancer receptor status

1. *Estrogen receptor (ER) expression.* The estrogen receptor status of a breast cancer determines whether or not anti-estrogenic endocrine therapy is indicated. Most breast cancers are estrogen receptor positive, and anti-estrogenic endocrine therapy will be recommended. The Selective Estrogen Receptor Modulator, (SERM), tamoxifen is effective in both pre- and postmenopausal patients due to its estrogen receptor antagonist activity in the breast. It is offered as initial therapy to *all* premenopausal women, irrespective of risk of recurrence. Postmenopausal women estimated to be at high or medium risk of recurrence are recommended initial treatment with aromatase inhibitors such as letrozole (Femara<sup>®</sup>), anastrozole (Arimidex<sup>®</sup>) and exemestane (Aromasin<sup>®</sup>), which reduce oestrogen synthesis in peripheral fat as trials suggest superiority to tamoxifen in this patient cohort. Tamoxifen is recommended as initial treatment in postmenopausal women at low risk of recurrence or those at higher risk unable to tolerate an aromatase inhibitor or where an aromatase inhibitor is contra-indicated.<sup>3</sup> The minimum duration of anti-estrogenic endocrine therapy is currently 5 years. Extended duration of therapy up to a maximum of 10 years can be offered or considered to further reduce risk of recurrence but this determined on an individual patient basis.<sup>3</sup>

In younger women at higher risk of recurrence gonadotrophin-releasing hormone agonists (e.g. goserelin [Zoladex<sup>®</sup>]) used in combination with aromatase inhibitors may be recommended, as such regimens are associated with less recurrence than with tamoxifen. The optimal treatment duration for such regimens is uncertain but currently is 5 years.<sup>3</sup>

2. *Human epidermal growth factor 2 receptor (HER2) expression.* Trastuzumab, a monoclonal antibody that blocks the HER2 receptor is indicated for cancers over-expressing this receptor (HER2 positive cancer).<sup>2</sup> Most breast cancers, however, do not over-express this receptor (i.e. HER2 negative cancer) and trastuzumab is not indicated. The treatment duration is for one year and it is used alongside chemotherapy and radiotherapy.<sup>3</sup>

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

## Breast cancer prognostic factors

1. Breast cancer prognostic factors are used by oncologists to estimate risk of systemic recurrence and inform decisions about the use of chemotherapy and other recurrence-reducing drugs such as bisphosphonates in women at higher risk of relapse. Prognostic factors include breast cancer axillary nodal status, tumour size, tumour grade, presence of lympho-vascular invasion and HER2 receptor over-expression. Genomic tests, which analyse the activity of groups of genes in an individual breast cancer are used to aid decisions about the use of chemotherapy in women with ER positive, HER2 negative cancer, who are estimated to be at indeterminate risk of recurrence using the non-genomic prognostic factors, above. Oncotype DX<sup>®</sup> was approved by NICE in 2013.<sup>9</sup> Ongoing research continues to evaluate other genomic tests such as EndoPredict<sup>®</sup> and up-dated NICE guidance is expected in late 2018.<sup>3,10</sup>
2. In early stage disease, chemotherapy is usually prescribed for a total of six to eight, three-weekly cycles and may be given before or after surgery.<sup>3</sup> In addition to a cytotoxic effect on malignant cells, chemotherapy has a cytotoxic effect on ovarian follicles, which may confer added therapeutic benefit in premenopausal women with hormone sensitive cancer.<sup>11</sup>
3. Bisphosphonates may be prescribed in the management of breast cancer treatment-induced bone loss, but recent clinical trial data have also shown reductions in bone recurrence and breast cancer mortality in postmenopausal women.<sup>11</sup> It is now recommended adjuvant bisphosphonate therapy is offered to postmenopausal women with lymph node positive breast cancer and considered in postmenopausal patients, without nodal involvement but whose cancers have other prognostic features, placing them at high risk of recurrence.<sup>3</sup>

## Follow-up for early breast cancer

The UK breast cancer follow-up pathway is in the process of change, with a move away from routine, out-patient-based appointments with clinical breast examination. There is no evidence this reduces breast cancer mortality or that it meets patients' supportive needs.<sup>3,12,13</sup> As an alternative, mammographic surveillance and patient self-management are being promoted at the completion of 'active' treatments (i.e. any or all of the following; surgery, chemotherapy, trastuzumab and radiotherapy). For women with ER negative cancer, in whom anti-estrogenic therapy is not indicated, no further treatment is required. In those women with ER positive cancer anti-estrogenic therapy is recommended for between 5 and 10 years.<sup>3,11</sup> Women with either ER positive or negative tumours may well present to primary care health workers with estrogen deficiency symptoms, whether due to a natural or chemotherapy-induced menopause, or symptoms attributable to tamoxifen or an aromatase inhibitor.

## Symptoms associated with adjuvant systemic therapy

### 1. Vasomotor symptoms

Idiopathic vasomotor symptoms induced by endocrine therapy or ovarian suppression have been reported to be more problematic and longer-lasting than those associated with a natural menopause. There is often a mismatch of perception between patients and health care professionals, with many women considering stopping treatment because of side effects for which management has never been discussed.<sup>6,14</sup> In premenopausal women the symptoms following a chemotherapy or GnRHa-induced ovarian suppression are usually more severe than those associated with tamoxifen.<sup>15,16</sup> The reported

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

persistence of symptoms after completion of tamoxifen in younger patients is probably due to prior chemotherapy exposure inducing an early menopause.<sup>16</sup> In postmenopausal women both tamoxifen and aromatase inhibitors are associated with induction of vasomotor symptoms.<sup>17</sup> Symptoms usually persist for the duration of exposure but their severity may decrease over time.<sup>18,19</sup>

## 2. Gynaecological symptoms and sexual dysfunction

Iatrogenic ovarian suppression, tamoxifen and aromatase inhibitors are all associated with symptoms attributable to vulvovaginal atrophy, which in turn can lead to dyspareunia and contribute to loss of sexual desire and reduced libido.<sup>20</sup> In contrast, in some women tamoxifen does not cause vaginal dryness but induces a mild non-purulent, non-itch producing white or clear vaginal discharge. This side-effect is likely to be due to the estrogenic effects of tamoxifen on the vagina and cervix. In postmenopausal women, aromatase inhibitors may induce more severe vulvovaginal symptoms than tamoxifen, vaginal dryness may worsen with increasing duration of therapy, and loss of libido can persist after completion of treatment.<sup>18,20</sup> Tamoxifen is associated with a small elevation in the risk of endometrial cancer in postmenopausal but not premenopausal patients by courtesy of its oestrogen-agonist effect on the postmenopausal endometrium (in premenopausal women, it does not appear to stimulate endometrial proliferation).<sup>21</sup> Overall endometrial cancers diagnosed in postmenopausal women are no different regarding stage, grade, histology and phenotype from those diagnosed in the general population.<sup>21</sup> In contrast, aromatase inhibitors are associated with no or a reduced risk.<sup>22</sup> It is hypothesised aromatase inhibitors may increase the risk of women developing symptoms of urogenital prolapse due to anti-oestrogenic effects on collagen but whilst preliminary clinical study suggests an adverse effect of faecal incontinence, no negative effect on urinary incontinence or pelvic organ prolapse has yet been reported.<sup>23</sup> Chemotherapy may also impact adversely on sexual function as a result of its other adverse effects such as hair loss, fatigue, weight gain and body image.<sup>20</sup>

## 3. Joint and musculoskeletal symptoms

Musculoskeletal symptoms associated with the use of aromatase inhibitors is estimated to affect just under one half of treated women.<sup>24,25</sup> They usually develop within a few months of commencing treatment and they may persist for the duration of use.<sup>7,26,27</sup> Common symptoms include morning stiffness and pain affecting the hands, knees, hips, lower back, and shoulders.<sup>7</sup> These most likely result from estrogen deprivation but inflammatory pathways and a tenosynovitis type effect with fluid retention in joints may also have a role in their aetiology.<sup>26</sup> Previous treatment with taxane-based chemotherapy, increases the risk of the development of aromatase inhibitor-induced arthralgia, but other predictors of these side effects are unclear.<sup>7,26</sup>

### Practice points

- I. Most women will receive a combination of systemic treatments.**
- II. Estrogen deficiency symptoms and aromatase inhibitor-induced arthralgia usually become apparent within a few months of starting therapies and may persist after treatment is completed.**
- III. Familiarity of the primary health care professionals with the type and duration of iatrogenic symptoms will aid consultation in primary care with breast cancer patients and appropriate referral for management.**
- IV. It is important to ask patients about symptoms associated with sexual dysfunction as often they will not volunteer this information spontaneously.**

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

## **Risk of early menopause associated with adjuvant systemic therapy**

Chemotherapy-induced ovarian suppression results in cessation of menstruation and for some women, this may be permanent, resulting in an early menopause and implications for future fertility.<sup>27</sup> The associated risk of an early menopause is related to age as it is more likely in those over the age of 40 consequent to natural ovarian follicle depletion and the regimen used, for example, alkylating agents such as cyclophosphamide are more gonadotoxic than taxanes.<sup>28,29</sup>

Tamoxifen has been reported to be associated with a small increased risk of developing an early menopause, when used alone or following chemotherapy.<sup>28</sup> With the former this descriptive association was restricted to women over 45 and probably reflects older age at exposure rather than a treatment effect. With respect to the latter, the menstrual irregularity or absence described is almost certainly due to the impact of prior chemotherapy and supported by a recent study suggesting no added impact of tamoxifen on ovarian reserve.<sup>28-34</sup>

Temporary ovarian suppression induced by short-term use of a GnRHa during neoadjuvant or adjuvant chemotherapy appears to reduce the risk of chemotherapy-induced premature ovarian insufficiency and may therefore maintain fertility.<sup>35</sup> When used as a therapeutic intervention in women with breast cancer, GnRHa are prescribed for a longer duration, that is between two to five years.<sup>3</sup> Irrespective of whether a GnRHa is commenced at the time of chemotherapy or after its completion, the proportion of women reporting an early menopause appears similar at approximately 20%, which again implies risk is attributable to chemotherapy exposure only.<sup>33</sup>

The impact of breast cancer and its treatment on fertility should be discussed as soon as possible after diagnosis, between women and their breast specialist team, especially in those recommended chemotherapy.<sup>36,37</sup> If fertility referral is appropriate and egg harvesting and cryopreservation recommended, this must be initiated prior to commencing treatment, however, this should not delay the start of therapy.<sup>36</sup> Women must be fit for ovarian stimulation and oocyte collection and estimated to have a good prospect for long-term survival.<sup>37</sup>

Most women, if they resume menstrual bleeding following completion of chemotherapy, do so within two years, however in about 10% of women menstruation, albeit irregular, may resume between three and five years after the last cycle of chemotherapy.<sup>32</sup> The risk of chemotherapy-induced amenorrhoea lasting more than two years is lower in women under the age of 39.<sup>32</sup> Whilst a return of menstruation may not indicate ovulatory cycles, amenorrhoea following chemotherapy may not signify infertility. As it is not possible to reliably predict which women may have been rendered infertile by treatment, it is reasonable to recommend non-hormonal contraception following chemotherapy for a minimum of two years to avoid unplanned pregnancy. If there has been amenorrhoea for two years, menopause can be confirmed by appropriate biochemical testing (see below).<sup>32</sup> If the results do not indicate menopause, contraception should be continued for a further year and testing repeated. Non-hormonal contraception is recommended if there is a history of breast cancer to reduce the risk of promoting an estrogen-sensitive recurrence or a new contralateral primary and to avoid increasing the risk of a venous thrombotic event. Barrier methods or the Cu-IUD are the preferred contraceptive choices. Emergency contraception may be used if indicated as it is extremely unlikely to cause any harm.<sup>38</sup>

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

In general, women who have undergone menopause before the age of 50 should use contraception until 2 years after their menopause. Women who have undergone menopause after the age of 50 should use contraception until one year after their last period.

## Diagnosis of the menopause in women treated for breast cancer

There is no agreed published consensus for the diagnosis of menopause in younger women treated for breast cancer. In the absence of such, the following is recommended:

1. If adjuvant systemic therapy in premenopausal women consists of tamoxifen alone, the diagnosis of menopause can be made if there has been amenorrhoea for at least twelve months combined with elevated FSH levels (i.e. FSH >30 IU/l) on two blood samples taken four to six weeks apart.<sup>1</sup> As serum FSH assays can be unreliable in the presence of tamoxifen, the latter should be stopped six to eight weeks in advance of performing this investigation.<sup>39</sup> This is of particular relevance for women eligible for extended adjuvant therapy, beyond 5 years' treatment with tamoxifen, where an aromatase inhibitor may be recommended if post-menopausal status is confirmed.<sup>3</sup>
2. Following chemotherapy exposure, the diagnosis of premature menopause may be based on a combination of the presence of menopausal symptoms, absence of menstruation and elevated FSH levels on two blood samples taken 4–6 weeks apart. In chemotherapy-treated women, amenorrhoea for two years is a reasonable time frame for suspecting the possibility of an early onset of menopause.<sup>32</sup> If tamoxifen is being used, it should be stopped for 6 to 8 weeks prior to checking serial FSH serum assays.
3. If a younger patient has completed treatment with a combination of a GnRHa and aromatase inhibitor (irrespective of prior chemotherapy use), a washout period of 12 weeks should be allowed in order to reverse the former's suppressive effect on the hypothalamic-pituitary axis before performing serial FSH assays.<sup>40</sup>
4. Preliminary clinical trial data suggests undetectable serum levels of anti-Müllerian hormone (using a highly sensitive assay) in women over 40 at completion of chemotherapy may be a reliable predictor of permanent ovarian failure and that the sensitivity and specificity of such assays may in addition be unaffected by concurrent tamoxifen exposure. However, larger, confirmatory trials are required before this is recommended for clinical practice.<sup>41,42</sup>

## Practice points

- I. It is the responsibility of a patient's specialist breast team to arrange fertility review if there is risk of fertility loss.**
- II. Women should be advised to use non-hormonal contraception if they have become amenorrhoeic.**
- III. If there is doubt about the diagnosis of menopause, referral to a specialist with expertise in menopause or reproductive medicine should be made.**

## Management of vasomotor symptoms, vulvo-vaginal atrophy and arthralgia

A number of recent evidence-based consensus position statements and guidelines have concluded lifestyle changes and non-hormonal alternatives to HRT should be first-line management for symptomatic women with a history of breast cancer. The maximum treatment for many studies, however, is 3 months, so the efficacy in the longer term is uncertain.<sup>43,44</sup>

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

In the UK, clinical practice is directed by the 2015 NICE Menopause Guidance (NG23) and the NICE guidance (NG101) on early and locally advanced breast cancer.<sup>1,3</sup> The conclusions of the 2015 menopause NICE guidance on interventions for vasomotor symptoms are limited for application in women with breast cancer as the statistical methodology relied on an analysis of evidence mainly from women without a diagnosis of breast cancer. Comparison of treatments was undertaken separately for women with and without breast cancer but data was very limited for the latter.<sup>45,46</sup> However, these are summarised with explanation and expansion as appropriate, below and where relevant, comparison with other publications.

## 1. General recommendations for the management of women with breast cancer<sup>1</sup>

- I. Offer information and counselling to breast cancer patients about:
  - a. The risk of possibility of developing an early menopause and menopausal symptoms associated with breast cancer treatment.
  - b. All management options, including lifestyle changes and interventions that could help general health and well-being.
  - c. The quality, purity and constituents of complementary therapies may be unknown (based on the lack of information on quality control, efficacy and safety about over-the-counter herbal preparations and complementary therapies).
- II. Refer breast cancer patients to a healthcare professional with expertise in the menopause.

## 2. Vasomotor symptoms

A recent Cochrane systematic review of placebo-controlled randomised trials in women with breast cancer have showed mild to moderate effect of clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy on reducing hot flushes in women with a history of breast cancer.<sup>47</sup>

The conclusion of the UK 2015 menopause guideline that selective serotonin release inhibitors [SSRI], selective noradrenaline release inhibitors [SNRI] and gabapentin should not be routinely offered as first-line therapy was based on the finding that although these are effective, compliance was very poor in trials reviewed because of side effects.<sup>1</sup> SSRIs and SNRIs may inhibit the activity of one of the main enzymes (i.e. CYP2D6) responsible for converting tamoxifen to its active metabolite and hence potentially reduce its anti-neoplastic action. This occurs to varying degrees and current recommendations are that paroxetine and fluoxetine, whose inhibitory action is strong, should be avoided in women treated with tamoxifen.<sup>1</sup>

- I. St John's wort may be effective in the treatment of hot flushes, but risk of interaction with tamoxifen, docetaxel and anti-coagulants raises safety issues for its use in this patient group. There is also uncertainty about the appropriate dose, persistence of efficiency and variation of potency of over-the-counter preparations.<sup>1</sup>
- II. Soy and red clover (isoflavones) have estrogenic activity and should be avoided in women with breast cancer.<sup>3</sup>
- III. Black cohosh, vitamin E and magnetic devices are not advised.<sup>3</sup>
- IV. Clonidine, SSRIs, SNRIs and gabapentin may alleviate symptoms as mild to moderate symptom benefit has been reported, but their effects can be outweighed by adverse effects.<sup>43,45,47,48</sup>
- V. The absence of government regulation (e.g. quality, purity of constituents) and clinical data supporting efficacy and safety for non-commercial bioidentical formulations, which in addition may contain active ingredients, has been highlighted in guidelines. Bioidenticals should be contra-indicated in women with breast cancer.<sup>1,49</sup>

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

VI. Consider cognitive behavioural therapy (CBT) to alleviate low mood or anxiety that arises as a result of the menopause.<sup>1,43,50</sup> A recent systematic review concluded that mindfulness, cognitive behavioural and behaviour-based therapy may be useful for the treatment of natural and treatment-induced menopausal symptoms since it alters perception of the symptoms rather than frequency.<sup>50</sup>

VII. Do not offer HRT routinely to women with menopausal symptoms and a history of breast cancer but *it may*, in exceptional cases, be offered to women with severe menopausal symptoms for whom other treatments have failed.<sup>3</sup> Any decision to prescribe HRT should involve the patient's specialist breast team and documented informed consent must be obtained, after associated risks and uncertainty have been explained. It should be appreciated that previous breast cancer is a contra-indication in all summaries of product characteristics for all types of HRT. It should not be prescribed in women treated with aromatase inhibitors as the therapeutic benefit of aromatase inhibitors is mediated via a reduction in endogenous estrogen synthesis.<sup>3,6</sup> It may be safe to prescribe HRT in women who are symptomatic on tamoxifen and although direct clinical evidence is lacking, the efficacy of tamoxifen in premenopausal patients despite high endogenous serum estrogen levels and lack of an increased risk of breast cancer diagnosis in tamoxifen chemoprevention trials that permitted the use of HRT imply this may be safe practice.<sup>51,52</sup>

The NICE Menopause Clinical Guidance Group (CGG) did not review lifestyle changes (e.g. use of portable fans, dressing in easily shed layers, avoiding triggers such as alcohol, weight loss) but advice about this should always be provided in the general advice for symptomatic women.<sup>6,43</sup>

The use of progestogens for symptom management in women with breast cancer is controversial due to their potential proliferative effect on occult breast cancer micro-metastases, as evidenced by the increased risk of diagnosis in women exposure to combined rather than unopposed HRT and absence of long-term efficacy and safety data.<sup>6</sup> No studies evaluating progestogens were reviewed by the NICE Menopause CGG as none met the selection criteria for inclusion and the NICE guidance on early and advanced breast cancer does not recommend their use in this patient group.<sup>1,3</sup>

Overall, lifestyle changes, SSRI, SNRIs, gabapentin, pregabalin, clonidine and CBT are recommended for the management of vasomotor symptoms. Research is ongoing to evaluate fully the efficacy and safety of other interventions including acupuncture, stellate ganglion block and newer pharmacological treatments such as neurokinin 3 receptor antagonists.<sup>6</sup> For individual women whose symptoms persist despite these measures, the NICE UK breast cancer guidance (NG101) is that systemic HRT *can* be considered, but not all international guidelines and position statements have adopted such a pragmatic approach.<sup>3,30,43,48,53</sup>

## Practice points

- I. If a patient develops vasomotor symptoms an indication of how troublesome they are likely to be can be estimated after about 3 to 6 months from the start of treatment as if vasomotor symptoms will reduce with time they usually do so at around 3 months.<sup>17</sup>**
- II. A variety of non-hormonal methods of treatment of vasomotor symptom are available to treat vasomotor symptoms and should be used first, in addition to lifestyle changes but if these are ineffective, systemic HRT may be considered.**

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

- III. Use of bioidentical preparations is contra-indicated.**
- IV. In postmenopausal patients, switching from an aromatase inhibitor to tamoxifen may alleviate vasomotor symptoms.**
- V. Systemic HRT should not be prescribed in women taking aromatase inhibitors.<sup>6</sup>**
- VI. It is not known if it is safe to prescribe HRT in women taking tamoxifen.**
- VII. No changes to breast cancer treatment or use of HRT should be initiated in primary care. Discussion with the breast specialist team is obligatory, as changes to treatment could potentially affect disease-free survival, particularly in higher-risk women.**
- VIII. In a symptomatic woman who has completed breast cancer therapy and been discharged from specialist follow-up, health care professionals in primary care should contact the patient's breast care nurse for advice as they are best placed to triage concerns and advise where to direct the patient.**

### 3. Vulvo-vaginal atrophy

- I. Commercially available vaginal moisturisers and vaginal lubricants are recommended as first-line treatment.<sup>1,54</sup> It has been suggested due to the weak oestrogenic activity of parabens, that lubricants containing these are avoided (e.g. K-Y jelly, Replens, Astroglide), however, clinical data to support or refute an adverse effect on women treated for breast cancer is completely lacking.<sup>55</sup>
- II. If symptoms persist, low-dose vaginal estrogen can be considered in women who have estrogen negative tumours or who are taking tamoxifen, but due to absence of clinical trial evidence confirming lack of an adverse effect, advice about prescribing should follow that as for systemic HRT, above, and should be discussed with the relevant oncology team.
- III. Low-dose vaginal estrogens should not be used in women taking aromatase inhibitors
- IV. The oral SERM, ospemifene, is not recommended for the treatment of refractory vaginal symptoms as there is a lack of any evidence about safety in women with breast cancer, although preclinical studies suggest a neutral effect on breast tissue.<sup>1,6</sup> Available studies only have short-term follow-up using unreliable surrogates for predicting future risk (i.e. clinical breast examination, change in mammographic breast density, breast tenderness).<sup>56</sup> The Food and Drug Administration and Endocrine Society support this recommendation against its use although The European Medicines Agency state it may be used after completion of breast cancer treatment.<sup>48,57,58</sup>

All guidelines and consensus statements concur with the recommendations of the NG23 for use of vaginal moisturizers and lubricants as initial treatment and consideration of low-dose topical estrogen if symptoms are refractory.<sup>6,43,48,51,53</sup>

Alternative interventions, which may be possible options for future management of symptoms in breast cancer patients include vaginal laser treatment (i.e. the fractional CO<sub>2</sub> and erbium lasers) and intravaginal dehydroepiandrosterone (DHEA) but both require further evaluation. Preliminary study of both laser treatments and DHEA for their short-term efficacy in breast cancer patients is encouraging.<sup>59-62</sup> For laser treatments, evidence of long-term efficacy and direct head-to-head comparison with topical oestrogen is necessary before informed recommendations can be made. DHEA has the theoretical advantage of local delivery of active estrogen and androgen metabolites via the activity of aromatase in vaginal epithelial cells, with minimal, probably clinically insignificant

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

increases in serum estradiol, estrion or free testosterone and appears efficacious in women treated with tamoxifen and aromatase inhibitors, the latter suggesting these may not impair intracellular, vaginal aromatase action. However, its safety in this group of women requires confirmation in clinical trials.<sup>54</sup>

## Practice points

- I. If symptoms of vulvo-vaginal atrophy are not relieved by vaginal moisturizers and lubricants:**
  - a. Topical estrogen should not be used if a woman is using an aromatase inhibitor due to concern systemic absorption (albeit very low) may negate the latter's efficacy.<sup>6</sup>**
  - b. If a woman is using an aromatase inhibitor, switching to tamoxifen may ameliorate symptoms. This beneficial effect can take up to three months to become evident.**
  - c. If switching to tamoxifen fails to improve symptoms, additional prescription of low-dose topical estrogen can be considered.**
  - d. No changes to breast cancer medication should be initiated in primary care. Discussion with the breast specialist team is obligatory, as changes to therapy could potentially affect disease-free survival, particularly in higher-risk women.**
- II. Ospemifene should not be prescribed to women with a history of breast cancer.**
- III. In addition to management of vulvo-vaginal atrophy, women with symptoms of sexual dysfunction may require referral for psycho-sexual counselling, education about use of vaginal dilators, pelvic floor relaxation techniques and support for management of body image concerns arising from previous breast surgery, treatment-induced hair loss or thinning or other reasons.<sup>30</sup>**
- IV. In a symptomatic woman who has completed breast cancer therapy and been discharged from specialist follow-up, health care professionals in primary care should contact the patient's breast care nurse for advice as they are best placed to triage concerns and advise where to direct the patient.**

## 4. Musculoskeletal symptoms

As yet, the optimal management of aromatase inhibitor-induced arthralgia is to be determined. A qualitative analysis of 19 studies (with meta-analysis of 15 of these) concluded pharmacological approaches, acupuncture, and relaxation techniques showed moderate to large effects on associated pain, but there was no significant impact with nutritional supplementation (i.e. glucosamine, omega-3 fatty acid, high dose vitamin D2).<sup>63</sup> None of the pharmacological studies, which evaluated switching of aromatase inhibitors, the SNRI duloxetine, prednisolone or immunological therapies were randomised or placebo-controlled and overall most of the studies reviewed were uncontrolled single patient group pre-test/post-test assessments, which raises concern about bias and reliability of outcomes. A recent randomised placebo-controlled trial has reported a significant reduction in average joint pain in women treated with aromatase inhibitors over a treatment period of three months with duloxetine, but discontinuation rates were high due to low grade toxicities experienced by significantly more of women allocated to receive duloxetine (e.g. fatigue, nausea, dry mouth, headache).<sup>64</sup> Evidence and advice about benefit of physical exercise is conflicting.<sup>7,63</sup>

No recommendations were made in the NICE menopause guidance, nor the recently up-dated NICE guidance on early and locally advanced breast cancer for the management of musculoskeletal symptoms induced by aromatase inhibitors.<sup>1,3</sup> One randomised study reviewed by the NICE menopause CCG showed improvements in physical functioning and bodily pain up to nine months

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

following group CBT versus usual care (i.e. patient access to clinical specialists and breast cancer support services).<sup>65</sup> However, musculoskeletal symptoms were not specifically assessed and the proportion of women taking aromatase inhibitors is unknown.

## **Practice points**

- I. In the absence of consensus and randomised controlled trials concerning the management of aromatase inhibitor-induced arthralgia it is reasonable to recommend hypermobilisation of the joints after periods of rest to reduce tenosynovitis type symptoms exercise, yoga, weight loss, a trial of regular paracetamol or systemic or locally delivered NSAIDs as first-line measures.**<sup>66-71</sup>
- II. If symptoms persist:**
  - a. Switching between non-steroidal aromatase inhibitors (letrozole, anastrozole) or between non-steroidal and steroidal (i.e. exemestane) aromatase inhibitors may be of some benefit.**<sup>72-74</sup>
  - b. Switching patients to tamoxifen from an aromatase inhibitor may be of benefit as the former is much less likely to induce arthralgia.**<sup>17</sup>
  - c. No changes to breast cancer medication should be initiated in primary care. Discussion with the breast specialist team is obligatory, as changes to therapy could potentially affect disease-free survival, particularly in higher-risk women.**

## **What evidence is available regarding the use of HRT for menopausal symptom relief in breast cancer survivors?**

Definitive evidence from clinical trials in women with previous breast cancer exposed to systemic HRT or topical estrogen is lacking. Three randomised trials of systemic HRT (with or without additional topical estrogen) were all stopped following an initial interim analysis from one trial group that showed an increased risk of recurrence. However, similar analyses from the other trial groups did not.<sup>74-76</sup> As all trials were stopped at an early stage, no firm conclusions can be made. Evidence from studies on the use of topical estrogen is also inconclusive as although none reported an increased risk of recurrence, their reliability is hampered by small event numbers and uncontrolled, observational methodology.<sup>77-82</sup> A large randomised trial of tibolone closed prematurely when interim analysis showed an increased risk of recurrence and also appeared to reduce the efficacy of concomitantly prescribed aromatase inhibitors, although this was not an *a priori* hypothesis.<sup>83</sup> It can be hypothesised HRT will not reduce the therapeutic impact of tamoxifen due to the latter's strong binding affinity for the estrogen receptor but it could negate the efficacy of aromatase inhibitors, which reduce oestrogen synthesis.

Breast cancer treatment and chemoprevention trials confirm estrogen deprivation or antagonism reduces the risk of the diagnosis and recurrence of hormone sensitive but not hormone insensitive breast cancer.<sup>3,84</sup> Concern exists therefore, HRT use will increase the risk of recurrence in estrogen receptor positive cancer and it is also important to be aware of the risk of late recurrence in this patient cohort, which may occur many years after treatment completion.<sup>85</sup> Furthermore, it may be incorrect to assume HRT is risk free in women with estrogen receptor negative disease as there is a very small risk of diagnosis of an estrogen receptor positive recurrence or a contralateral breast primary in this patient group.<sup>86,87</sup> Additional factors, which could influence risk, include time from breast cancer diagnosis, extent of breast surgery and concurrent use of tamoxifen. However, these, along with cancer estrogen

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

receptor status have not been confirmed or refuted in published clinical evidence to date. A final consideration is whether HRT is efficacious in symptomatic women taking tamoxifen. One breast cancer chemoprevention trial found that systemic HRT was not but randomised trials of HRT in breast cancer patients suggests otherwise.<sup>76,88,89</sup>

Some patients, after trying alternatives to HRT for symptom relief unsuccessfully, may request to have systemic or local oestrogen. Counselling such women should account for these prevailing uncertainties. Whilst NICE and the UK National Cancer Research Institute Symptom Management Breast Group recommend research investigating non-hormonal alternatives for symptom management, NICE has identified a need for clinical trials evaluating the safety of systemic and topical HRT in specific patient cohorts (e.g. women with estrogen receptor negative cancer or those with estrogen receptor positive disease taking tamoxifen).<sup>1-14</sup>

## References

1. www.NICE.org.uk Menopause: diagnosis and management. NICE guidelines [NG23] Published date November 2015
2. www.cancerresearchuk.org Cancer Research UK
3. www.NICE.org.uk Early and locally advanced breast cancer: Diagnosis and treatment. NICE guidance [NG101] Published date July 2018.
4. Plevritis SK, Munoz D, Kurian AW et al. Association on screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. *JAMA*. 2018; 319:154-164
5. Murphy CC, Bartholomew L, Carpentier M et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. *Breast Cancer Res Treat*. 2012; 134:459-478
6. Santen RJ, Stuenkel CA, Davis SR et al. Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. *J Clin Endocrinol Metab*. 2017; 102:3647-3661
7. Beckwee D, Leysen L, Meuwis K et al. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. *Support Care Cancer* 2017; 25: 1673-1686
8. Cruickshank S, Hume A. The experience of providing support about menopausal symptoms to breast cancer patients. *Eur J Oncol Nurs* 2014; 18: 110-117.
9. www.NICE.org.uk Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. Diagnostics guidance [DG10] Published date: September 2013
10. www.breastcancernow.org
11. Curigliano G, Burstein, HJ, Winer EP et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Annals of Oncol* 2017; 28: 1700-1712.
12. www.ncsi.org.uk National Cancer Survivorship Initiative
13. www.macmillan.org.uk Follow-up care – Information and support
14. Morgan A, Ah-See A-L, Hunter M et al. Comparing clinician and patient perspectives in the management of hot flushes in UK breast cancer patients. NCRI Breast CSG Symptom Management Subgroup. *Breast Cancer Res Treat*. 2018. P6.9 Abstract 1st Interdisciplinary Breast Cancer Symposium 15th-16th January 2018. <https://doi.org/10.1007/s10549-017-4585-x>
15. Azim HA, Davidson NE, Ruddy KJ. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. *Am Soc Clin Oncol Educ Book* 2016; 35:23-32

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

16. Nystedt M, Berglund G, Bolund C et al. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. *J Clin Oncol* 2003; 21:1836-1844
17. Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. *Breast Cancer Res Treat* 2008; 107:167-180
18. Fallowfield LJ, Kilburn LS, Langridge C et al. Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. *Br J Cancer* 2012; 106:1062-1067
19. Love RR, Feyzi JM. Reduction in vasomotor symptoms from tamoxifen over time. *J Natl Cancer Inst.* 1993 Apr 21;85(8):673-4.
20. Sears CS, Robinson JW, Walker LM. A comprehensive review of sexual health concerns after cancer treatment and the biopsychosocial treatment options available to female patients *Eur J Cancer Care* 2017; e12738. <https://doi.org/10.1111/ecc12738>
21. ACOG Committee Opinion No. 601: Tamoxifen and Uterine Cancer. *Obstet Gynecol* 2014; 1223: 1394-1397
22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*, 2015; 386: 1341-1352
23. Robinson PJ, Bell RJ, Christakis MJ et al. Aromatase Inhibitors Are Associated with Low Sexual Desire Causing Distress and Fecal Incontinence in Women: An Observational Study. *J Sex Med*, 2017; 14: 1566 - 1574
24. Henry NL, Azzouz F, Desta Z, et al: Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. *J Clin Oncol* 2012; 30: 936-942
25. Crew KD, Greenlee H, Capodice J, et al: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. *J Clin Oncol* 2007; 25: 3877-3883
26. Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. *Breast Cancer Research* 2011; 13: 205
27. Kyvernatakis I, Ziller V, Hars O et al. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. *Climacteric* 2014; 17: 252-9. doi: 10.3109/13697137.2013.819327.
28. Goodwin PJ, Ennis M, Pritchard KI et al. Risk of menopause during the first year after breast cancer diagnosis. *J Clin Oncol* 1999; 17: 2365-2370
29. Petrek JA, Naughton MJ, Case LD et al. Incidence, Time Course, and Determinants of Menstrual Bleeding After Breast Cancer Treatment: A Prospective Study. *J Clin Oncol* 2006; 24: 1045-1051
30. Runowicz CD, Leach CR, Henry NL et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. *J Clin Oncol* 2016; 34: 611-635.
31. Lambertini M, Del Mastro L, Pescio MC et al. Cancer and fertility preservation: international recommendations from an expert meeting. *BMC Med* 2016; 14: 1-16
32. Sukumvanich P, Case LD, Kimberly Van Zee K et al. Incidence and Time Course of Bleeding After Long-Term Amenorrhea After Breast Cancer Treatment A Prospective Study. *Cancer* 2010; 116: 3102-3011
33. Zhang Y, Ji Y, Li J et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival. *Breast Cancer Res Treat* 2018;168: 679-686
34. Shandley LM, Spencer JB, Fothergill A et al. Impact of tamoxifen therapy on fertility in breast cancer survivors. *Fertil Steril*, 2017; 107: 243-252.e5

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

35. Lambertini M, Moore HCF, Leonard RCF et al. Gonadotrophin-Releasing Hormone Agonists during Chemotherapy for preservation of Ovarian Function and Fertility in Premenopausal Patients with Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. *J Clin Oncol* 2018; 36: 1981-1990
36. www.NICE.org.uk Fertility problems: assessment and treatment. NICE guidelines [CG156] Published date February 2013, updated September 2017
37. Yasmin E, Balachandren N, Davies MC et al. Fertility preservation for medical reasons in girls and women: British fertility society policy and practice guideline. 2018; *Human Fertility*, 21: 3-26
38. Marsden J. Hormonal contraception and breast cancer, what more do we need to know? *Post Reprod Health*. 2017; 23: 116-127
39. Lonning PE, Johannessen DC, Lien EA et al. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. *J Steroid Biochem Mol Biol* 1995; 52:491-496
40. Cockshott ID. Clinical pharmacokinetics of goserelin. *Clin Pharmacokinet*. 2000; 39:27-48. DOI: 10.2165/00003088-200039010-00003
41. Anderson RA, Mansi J, Coleman RE, et al. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. *Eur J Cancer*, 2017; 87: 58-64
42. Iwase A, Nakamura T, Nakahara T et al. Anti-Müllerian Hormone and Assessment of Ovarian Reserve After Ovarian Toxic Treatment: A Systematic Narrative Review. 2015, *Reprod Sci*, 2015; 22: 519 - 526
43. Position Statement: Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. *Menopause. The Journal of The North American Menopause Society*. 2015; 22: 1155-1174.
44. Johns C, Seav SM, Dominick SA et al. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. *Breast Cancer Res Treat*. 2016; 156:415-426.
45. Marsh M. Hormones, Damned Hormones and Statistics. *BJOG*. 2017; 124: 1465-1466
46. Sarri G, Pedder H, Dias S et al. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. *BJOG* 2017; 124: 1514-1523.
47. Rada G, Capurro D, Pantoja T et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. *Cochrane Database of Systematic Reviews* 2010, Issue 9. Art. No.: CD004923. DOI: 10.1002/14651858.CD004923.pub2.
48. Stuenkel CA, Davis SR, Gompel A. Treatment of symptoms of Menopause: An Endocrine Society Practice Guideline. *J Clin Endocrinol Metab*. 2015; 100: 3975-4011
49. www.thebmw.org.uk Panay N, on behalf of the British Menopause Society. BMS consensus statement: bioidentical hormones. September 2017
50. van Driel CMG, Stuursma AS, Schroevers MJ et al. Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. *BJOG* 2018; epublished 15th March 2018 <https://doi.org/10.1111/1471-0528.15153>.
51. Sherman BM, Chapler FK, Crickard K et al, Endocrine Consequences of Continuous Antiestrogen Therapy with Tamoxifen in Premenopausal Women. *J Clin Invest* 1979; 64: 398-404.
52. Cuzick J, Sestak I, Cawthorn S et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. *Lancet Oncol* 2015; 16: 67-75.

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

53. Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 126: Management of gynecologic issues in women with breast cancer. *Obstet Gynecol*, 2012; 119: 666-682
54. Faubion SS, Larkin LC, Stuenkel CA et al NAMS Consensus Recommendations. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. *Menopause*, 2018; 25: 596-608
55. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? *Climacteric*, 2016; 19: 151-161
56. Simon JA, Altomare C, Cort S et al. Overall safety of Ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. *J Womens Health* 2018; 27: 14-23.
57. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/203505s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203505s000lbl.pdf) [Accessed 6 February 2018]
58. European Medicines Agency . Sensio Summary of Product Characteristics. EMA; 2015. [https://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_Product\\_Information/human/002780/WC500182775.pdf](https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002780/WC500182775.pdf) [Accessed 8 February 2018]
59. Becorpi A, Campisciano G, Zanotta N et al. Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects *Lasers Med Sci*, 2018; 33: 1047-1054
60. Gambacciani M, Levancin M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. *Menopause*, 2017; 24: 316–319
61. Barton DL Sloan JA, Shuster LT et al. Evaluating the efficacy of vaginal dehydroepiandrosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). *Support Care Cancer*, 2018, 26: 643-50
62. Barton DL, Shuster LT, Dockter T et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). *Support Care Cancer*, 2018; 26: 1335-1343
63. Yang GS, Kim HJ, Griffith KA, et al: Interventions for the treatment of aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review and meta-analysis. *Cancer Nurs* 2017; 40: E26-E41.
64. Henry NL, Unger JM, Schott AF, et al: Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. *J Clin Oncol* 2018; 36:326-332
65. Mann E, Smith MJ, Hellier J et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. *Lancet Oncol* 2012; 13: 309-318.
66. Nahm N, Mee S, Marx G. Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review. *Asia Pac J Clin Oncol*. 2018 Jan 30. doi: 10.1111/ajco.12845.)
67. Morales L, Pans S, Paridaens R, et al Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. *Breast Cancer Res Treat*. 2007; 104: 87-91.
68. Niravath P. Aromatase inhibitor-induced arthralgia: a review. *Ann Oncol*. 2013; 24: 1443–1449.
69. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. *Curr Oncol*. 2007; 14: S11–S19.

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

70. Younus J, Kligman L. Management of aromatase inhibitor-induced arthralgia. *Curr Oncol*. 2010; 17: 87–90.
71. Menas P, Merkel D, Hui W et al. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. *J Oncol Pharm Pract*. 2012;18(4):387–393.
72. Briot K, Tubiana-Hulin M, Bastit L et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. *Breast Cancer Res Treat* 2010, 120:127-134.
73. Kadakia KC, Kidwell KM, Seewald NJ et al. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. *Breast Cancer Res Treat* 2017; 164: 411-419.
74. Holmberg L, Iverson OE, Rudenstam CM et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. *J Natl Cancer Inst* 2008; 100: 475-82.
75. Fahlén M, Fornander T, Johansson H et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. *Eur J Cancer*. 2013; 49: 52-59
76. Marsden J, Morden J, A'Hern R et al on behalf of the UK HRT Trial Management Group. Hormone replacement therapy (HRT) is effective in relieving estrogen deficiency symptoms (ODS) and improves quality of life in breast cancer patients: The UK randomised HRT trial experience. *Maturitas* 2017; 132 DOI: <https://doi.org/10.1016/j.maturitas.2017.03.286> [Accessed 8 February 2018].
77. Vassilopoulou-Sellin R Vassilopoulou-Sellin R, Theriault RL et al. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. *Gynecol Oncol* 1997; 65: 89–93.
78. O'Meara ES, Rossing MA, Daling JR et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. *J Natl Cancer Inst* 2001; 93: 754–762
79. Durna EM, Wren BG, Heller GZ et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. *Med J Aust* 2002; 177: 347-351.
80. Dew JE, B. G. Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. *Climacteric* 2002; 5: 151-155.
81. Dew JE, B. G. Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. *Climacteric* 2003; 6: 45-52.
82. Le Ray I, Dell'Aniello S, Bonnetain F et al. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. *Breast Cancer Res Treat*. 2012 Sep;135(2):603-9.
83. Kenemans P, Bundred NJ, Foidart JM et al; LIBERATE Study group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. *Lancet Oncol*. 2009; 10: 135-46.
84. [www.nice.org.uk](http://www.nice.org.uk) Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Clinical guideline [CG164] Published date: June 2013, updated: March 2017.
85. Colleoni M, Sun Z, Price KN, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results from the International Breast Cancer Study Group Trials I to V. *J Clin Oncol*. 2016; 34: 927-35.
86. Lower EE, Khan S, Kennedy D et al. Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. *Breast Cancer* 2017; 9: 515-52

# The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

87. Mezencev M, Švajdler M. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries. *Breast Cancer* 2017; 24: 400-410.
88. Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. *J Clin Oncol.* 2006; 24: 3991-3996.
89. Fahlen M, Wallberg B, von Schoultz E et al. Health-related quality of life during hormone therapy after breast cancer: a randomized trial. *Climacteric* 2011; 14: 164-170.

*Miss Jo Marsden, Consultant Breast Surgeon, King's College Hospital, London, Mr Mike Marsh, Consultant Gynae-endocrinologist, King's College Hospital, London, Dr Anne Rigg, Consultant Medical Oncologist, Guy's and St Thomas' Hospital, London on behalf of The British Menopause Society, on behalf of the British Menopause Society medical advisory council.*

WRITTEN: NOVEMBER 2018  
NEXT REVIEW DATE: NOVEMBER 2020



For further details – please visit

[www.thebms.org.uk](http://www.thebms.org.uk) or telephone **01628 890 199**

